Minaris invests to triple capacity in Europe – Bioprocess Insider – BioProcess Insider

The cell and gene therapy CDMO will build additional facilities at its German and Japanese locations.

The contract development and manufacturing organization (CDMO) specializing in cell and gene therapies announced two separate investments of $40.7 million (34.2 million) into its Ottobrunn, Germany, site, and $23.8 million for its Yokohama, Japan, site.

Both regions now come under the umbrella of Minaris Regenerative Medicine, a subsidiary of Showa Denko Materials, after a rebrand in September to unify the name of its three businesses located in North America (previously, Hitachi Chemical Advanced Therapeutics Solutions (HCATS)), Europe (apceth Biopharma), and Japan (Hitachi Chemical).

Image: iStock/oatawa

The Japanese company acquired apceth last year for $86 million and will now add a 6,650-square-meter facility to the German site. The space will include additional clean rooms, quality control laboratories, warehousing, cryo-storage and office space.

Once operational in 2023, the facility will more than triple the current clean room capacity.

A spokesperson for Minaris explained that the facility will feature a modular design, which allows the company to combine two smaller units into one large ball room and to shift from a grade B to grade C to grade B environment according to our clients needs.

The European site became one of the first CDMOs to manufacture a commercial gene therapy, after agreeing a deal with bluebird bio to manufacture its Zynteglo (autologous CD34+ cells encoding A-T87Q-globin gene) product last year.

While the companys Japanese site will also receive an additional facility, which will cover 4,000-square-meters and is scheduled to start operations in October 2022.

The space will be used specifically for the commercial manufacture of regenerative medicine, particularly cancer immunotherapies and somatic stem cells, doubling the sites existing capacity.

Minaris global presence for a cell and gene specialist is unusual for an industry often concentrated in the US. However, the spokesperson for Minaris outlined that a global position confers an advantage to our clients that are seeking a global manufacturer to produce their product in different regions for example, clients with autologous cell products that need a manufacturing site close to the patients.

Additionally, We have regulatory expertise in Europe, Japan and the US and can leverage the expertise of one region to another, the spokesperson added.

Read the rest here:
Minaris invests to triple capacity in Europe - Bioprocess Insider - BioProcess Insider

Cell Therapy Manufacturing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 – PRnews Leader

Prophecy Market Insights added a recent Cell Therapy Manufacturing market report with Revenue, Key Developments, Top Countries Data, SWOT Analysis, COVID-19 impact, Growth and Outlook To 2029 to its research database. The report includes analysis of different factors that drives the market growth. It includes drivers, restrains, opportunities, and trends for the market. Further, the report provides the scope of different segments and applications which can promote the market over the forecast period. The in-depth information is based on historic milestones and current trends.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The report offers detailed information of the growth and other aspects of the Cell Therapy Manufacturing market in different regions, including North America, Europe, Asia pacific, and Middle East & Africa. Key regions covered in the report are the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc.

Australia, New Zealand, Rest of Asia-Pacific

Further, the report also provides the economic, environmental, social, technological, and political status of each region. This section also analyses region-wise revenue and volume for the forecasted period 2019-2029.

Cell Therapy Manufacturing Market by Top Manufacturers:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Competitive landscape section of the Cell Therapy Manufacturing report includes top ten manufacturers along with heat map analysis. The comprehensive report provides a significant microscopic look offering product portfolio, key highlights, financial overview, and business strategies.

Key Takeaways of the market report:

Key Topics Covered:

Important Questions Answered in Cell Therapy Manufacturing Market Report:

Segmentation Overview:

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/21

Reasons to purchase the XYX market:

Provides recent collaborations, mergers, acquisitions, and partnerships along with regulatory framework across vast regions impacting the market trajectory

Report Scope

Europe

Asia Pacific

Latin America

Middle East & Africa

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See the original post:
Cell Therapy Manufacturing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - PRnews Leader